Pharmo Institute

A functionally distinct HPA ‐1a‐specific alloantibody associated with fetal/neonatal alloimmune thrombocytopenia that activates platelets via FcγRIIa

Abstract Background Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against fetal platelet antigens, most commonly human platelet antigen‐1a (HPA‐1a). These antibodies mediate platelet destruction and can lead to fetal and neonatal...

Associations of frailty and COVID-19 severity with long-term health outcomes of COVID-19 among older people

To investigate whether frailty and COVID-19 severity are associated with long-term health outcomes of COVID-19 in older people. In this cohort study, older people aged ≥ 70 years with COVID-19 between January 2020 and December 2021 were invited for follow-up. Participants were re...

Co-Encapsulation and In Vitro Gastrointestinal Release of Gallic Acid and Curcumin: A Comparison between Double Emulsions and Templated Core-Laden Bubble Systems

Abstract This study examines how the intermediate phase in hierarchical colloidal carriers influences the co-encapsulation and in vitro gastrointestinal release of hydrophilic gallic acid and hydrophobic curcumin, using double emulsions (DE; W1/O/W2) and templated core-laden bubb...

SOLiD‐MaP: A Photoproximity Labeling Platform for Small Molecule Binding Site Mapping on RNA

RNA-targeting small molecules are emerging as promising therapeutic modalities, but their development requires methods that define binding sites and evaluate RNA target selectivity. Existing approaches for detecting ligand-RNA interactions have provided powerful foundations, yet...